Immunohistochemistry for Ki-67 exhibited the presence of abundant proliferating tumor cells in the DMSO treated samples but not in the C1 treated ones (p<0.0026; Fig. 3D), suggesting that C1 treatment suppressed GBM cell proliferation in situ. The gene discussed is MKI67; the disease is glioblastoma.